Cantor Fitzgerald raised the firm’s price target on Monopar Therapeutics (MNPR) to $109 from $74 and keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- CoreWeave upgraded, Lululemon downgraded: Wall Street’s top analyst calls
- Monopar Therapeutics initiated with a Buy at Lake Street
- Monopar Therapeutics management to meet virtually with Piper Sandler
- Promising Long-Term Efficacy and Safety of ALXN1840 Strengthens Buy Rating for Monopar Therapeutics Inc.
- Monopar Therapeutics Presents New Data on ALXN1840